Pegozafermin (BIO89-100) is a long-acting, glycopegylated FGF21 analog developed for the treatment of nonalcoholic steatohepatitis and hypertriglyceridemia.[1][2][3][4]
| Clinical data | |
|---|---|
| Other names | BIO89-100; TEV-47948 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
References
edit- ^ Loomba, Rohit; Sanyal, Arun J.; Kowdley, Kris V.; Bhatt, Deepak L.; Alkhouri, Naim; Frias, Juan P.; Bedossa, Pierre; Harrison, Stephen A.; Lazas, Donald; Barish, Robert; Gottwald, Mildred D.; Feng, Shibao; Agollah, Germaine D.; Hartsfield, Cynthia L.; Mansbach, Hank; Margalit, Maya; Abdelmalek, Manal F. (14 September 2023). "Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH". New England Journal of Medicine. 389 (11): 998–1008. doi:10.1056/NEJMoa2304286. PMC 10718287.998-1008&rft.date=2023-09-14&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10718287#id-name=PMC&rft_id=info:doi/10.1056/NEJMoa2304286&rft.aulast=Loomba&rft.aufirst=Rohit&rft.au=Sanyal, Arun J.&rft.au=Kowdley, Kris V.&rft.au=Bhatt, Deepak L.&rft.au=Alkhouri, Naim&rft.au=Frias, Juan P.&rft.au=Bedossa, Pierre&rft.au=Harrison, Stephen A.&rft.au=Lazas, Donald&rft.au=Barish, Robert&rft.au=Gottwald, Mildred D.&rft.au=Feng, Shibao&rft.au=Agollah, Germaine D.&rft.au=Hartsfield, Cynthia L.&rft.au=Mansbach, Hank&rft.au=Margalit, Maya&rft.au=Abdelmalek, Manal F.&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10718287&rfr_id=info:sid/en.wikipedia.org:Pegozafermin" class="Z3988">
- ^ Bhatt, Deepak L.; Bays, Harold E.; Miller, Michael; Cain, James E.; Wasilewska, Katarzyna; Andrawis, Nabil S.; Parli, Teresa; Feng, Shibao; Sterling, Lulu; Tseng, Leo; Hartsfield, Cynthia L.; Agollah, Germaine D.; Mansbach, Hank; Kastelein, John J. P. (July 2023). "The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial". Nature Medicine. 29 (7): 1782–1792. doi:10.1038/s41591-023-02427-z. ISSN 1546-170X. PMC 10353930.1782-1792&rft.date=2023-07&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353930#id-name=PMC&rft.issn=1546-170X&rft_id=info:doi/10.1038/s41591-023-02427-z&rft.aulast=Bhatt&rft.aufirst=Deepak L.&rft.au=Bays, Harold E.&rft.au=Miller, Michael&rft.au=Cain, James E.&rft.au=Wasilewska, Katarzyna&rft.au=Andrawis, Nabil S.&rft.au=Parli, Teresa&rft.au=Feng, Shibao&rft.au=Sterling, Lulu&rft.au=Tseng, Leo&rft.au=Hartsfield, Cynthia L.&rft.au=Agollah, Germaine D.&rft.au=Mansbach, Hank&rft.au=Kastelein, John J. P.&rft_id=https://www.nature.com/articles/s41591-023-02427-z&rfr_id=info:sid/en.wikipedia.org:Pegozafermin" class="Z3988">
- ^ Loomba, Rohit; Lawitz, Eric J; Frias, Juan Pablo; Ortiz-Lasanta, Grisell; Johansson, Lars; Franey, Bridgette Boggess; Morrow, Linda; Rosenstock, Moti; Hartsfield, Cynthia L; Chen, Chao-Yin; Tseng, Leo; Charlton, R Will; Mansbach, Hank; Margalit, Maya (February 2023). "Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study". The Lancet Gastroenterology & Hepatology. 8 (2): 120–132. doi:10.1016/S2468-1253(22)00347-8.120-132&rft.date=2023-02&rft_id=info:doi/10.1016/S2468-1253(22)00347-8&rft.aulast=Loomba&rft.aufirst=Rohit&rft.au=Lawitz, Eric J&rft.au=Frias, Juan Pablo&rft.au=Ortiz-Lasanta, Grisell&rft.au=Johansson, Lars&rft.au=Franey, Bridgette Boggess&rft.au=Morrow, Linda&rft.au=Rosenstock, Moti&rft.au=Hartsfield, Cynthia L&rft.au=Chen, Chao-Yin&rft.au=Tseng, Leo&rft.au=Charlton, R Will&rft.au=Mansbach, Hank&rft.au=Margalit, Maya&rfr_id=info:sid/en.wikipedia.org:Pegozafermin" class="Z3988">
- ^ Alkhouri, Naim; Lazas, Donald; Loomba, Rohit; Frias, Juan P.; Feng, Shibao; Tseng, Leo; Balic, Kemal; Agollah, Germaine D.; Kwan, Tinna; Iyer, Janani S.; Morrow, Linda; Mansbach, Hank; Margalit, Maya; Harrison, Stephen A. (November 2023). "Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy‐confirmed nonalcoholic steatohepatitis". Alimentary Pharmacology & Therapeutics. 58 (10): 1005–1015. doi:10.1111/apt.17709.1005-1015&rft.date=2023-11&rft_id=info:doi/10.1111/apt.17709&rft.aulast=Alkhouri&rft.aufirst=Naim&rft.au=Lazas, Donald&rft.au=Loomba, Rohit&rft.au=Frias, Juan P.&rft.au=Feng, Shibao&rft.au=Tseng, Leo&rft.au=Balic, Kemal&rft.au=Agollah, Germaine D.&rft.au=Kwan, Tinna&rft.au=Iyer, Janani S.&rft.au=Morrow, Linda&rft.au=Mansbach, Hank&rft.au=Margalit, Maya&rft.au=Harrison, Stephen A.&rft_id=https://doi.org/10.1111%2Fapt.17709&rfr_id=info:sid/en.wikipedia.org:Pegozafermin" class="Z3988">
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |